Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
Structure of 1492056-71-9
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Amino-PEG4-Val-Cit-PAB-MMAE, a pivotal linker-drug conjugate, is commonly harnessed in the development of antibody-drug conjugates (ADCs) for precision cancer therapy. Here are four key applications presented with heightened perplexity and burstiness:
ADCs Development: Amino-PEG4-Val-Cit-PAB-MMAE plays a crucial role in crafting potent and selective ADCs designed to target specific cancer cells. The linker facilitates the secure attachment of MMAE, a potent cytotoxic agent, to the antibody, enabling targeted delivery to malignant tissues. This strategy not only minimizes systemic toxicity but also maximizes antitumor efficacy, leading to a paradigm shift in cancer treatment precision.
Cancer Research: In the realm of preclinical cancer investigations, this compound stands as a cornerstone for assessing the efficacy and safety of novel ADCs. Utilizing this linker-drug conjugate, researchers conduct comprehensive in vitro and in vivo experiments to evaluate its impact on tumor dynamics and survival rates. The insights gained aid in pinpointing promising ADC candidates for further escalations into clinical development, fueling advancements in personalized oncology care.
Pharmaceutical Analysis: Amino-PEG4-Val-Cit-PAB-MMAE finds its niche in quality control and analytical scrutiny, ensuring the stability and bioactivity of ADCs. Leveraging sophisticated analytical methodologies such as mass spectrometry and HPLC, experts monitor the conjugation efficiency and purity of ADCs with precision. This meticulous oversight guarantees the consistent performance and safety profile of drug candidates, paving the way for reliable therapeutic interventions.
Targeted Drug Delivery Systems: Beyond the realms of cancer therapy, the versatility of Amino-PEG4-Val-Cit-PAB-MMAE extends to tailored drug delivery systems for diverse therapeutic agents. Through conjugating various bioactive molecules to the linker, researchers engineer innovative drug delivery platforms for a spectrum of disease domains. This application broadens the horizons of this compound, ushering in a new era of targeted therapeutic interventions across multifaceted medical landscapes.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00019 | Fmoc-VC-PAB-MMAE | 1350456-56-2 | |
BADC-00849 | Acetylene-linker-Val-Cit-PABC-MMAE | 1411977-95-1 | |
BADC-01448 | mDPR-Val-Cit-PAB-MMAE | 1491152-26-1 | |
BADC-01348 | Val-Cit-PAB-MMAE TFA salt | 1608127-32-7 | |
BADC-01435 | N-Ac-Cys-MC-VC-PAB-MMAE | 1628933-80-1 | |
BADC-01408 | DBM(C6)-VC-PAB-MMAE | 1644228-55-6 | |
BADC-01459 | MC-betaglucuronide-MMAE-1 | 1703778-92-0 | |
BADC-01638 | OH-Glu-Val-Cit-PAB-MMAE | 1895916-23-0 | |
BADC-00855 | SuO-Glu-Val-Cit-PAB-MMAE | 1895916-24-1 | |
BADC-01413 | DBM-MMAE | 1912408-87-7 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.